IQV IQVIA Holdings, Inc. Common Stock
O IQVIA Holdings, Inc. Common Stock Przegląd firmy z Wikipedii
IQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.
Czytaj więcej
IQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.
IQVIA operates through three business segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Through its technology and analytics business, the company maintains access to more than one billion supposedly anonymized patient records globally, and provides healthcare data, analytics, and software services to life science organizations, health care centers like hospitals, and pharmacists worldwide. This participates in extending their access to personal health data around the globe.
The company was formed in 2016 through the merger of Quintiles, a contact research organization, and IMS Health, a healthcare data and analytics provider. The combined company operated as QuintilesIMS before adopting the name IQVIA in 2017. The IQVIA name is a combination of: I (IMS Health), Q (Quintiles), and VIA (by way of).
History
The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services.
IMS Health
The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib.
In 1998, the parent company, Cognizant Corporation, split into two companies: IMS Health and Nielsen Media Research. After this restructuring, Cognizant Technology Solutions became a public subsidiary of IMS Health
In 2002, IMS Health acquired Cambridge Pharma Consultancy, a privately held international firm that provides strategic advice to pharmaceutical management.
In 2002, IMS Health acquired the Rosenblatt Klauber Group, a privately held international consultancy that provides forecasting, opportunity assessment & management development services to pharmaceutical companies.
In 2003, acquired Marketing Initiatives, a specialist in healthcare facility profile data, and Data Niche Associates, a provider of rebate validation services for Medicaid and managed care. In 2003, IMS Health sold its entire 56% stake in Cognizant and both companies are separated into two independent entities as IMS Health and Cognizant
In 2004, United Research China Shanghai was acquired, providing coverage of China's consumer health market.
In 2005, acquired PharMetrics, a U.S. provider of patient-centric integrated claims data.
In 2006, acquired the Life Sciences practice of Strategic Decisions Group, a portfolio strategy consultant to the life sciences industry.
In 2007, IMS Health acquired IHS and MedInitiatives, providers of healthcare data management analytics and technology services. That same year, ValueMedics Research was acquired, extending IMS Health's health economics and outcomes research capabilities.
In 2007, ranked in the Businessweek 50. This list represents "best in class" companies from the ten economic sectors that make up the S&P 500.
In 2008, named to the World's Most Admired Companies list by Fortune. The company received the recognition again in 2010.
In 2008, acquired RMBC, a provider of national pharmaceutical market intelligence and analytics in Russia.
In 2008, acquired the Skura professional services group, based out of Mississauga, Ontario, Canada and specialized in data integration, consulting and services in business intelligence platforms to pharmaceutical and healthcare clients in North America and Europe.
In 2009, named to the Dow Jones Sustainability North America Index in recognition of the company's economic, environmental and social performance among the largest 600 North American companies.
In February 2010, IMS Health was taken private by TPG Capital, CPP Investment Board, and Leonard Green & Partners.
In 2010, acquired Brogan, Inc., a privately held market research and consulting firm serving the Canada healthcare market.
In 2011, expanded its specialty and patient-level data assets in the United States with the acquisition of SDI Health. Also that year, the company acquired Ardentia Ltd in the UK, and Med-Vantage in the United States to build on its payer services in those markets.
In 2012, acquired PharmARC Analytic Solutions Pvt. Ltd, a Bangalore-based analytics company.
In 2012, acquired DecisionView, a software solutions company that helps life sciences organizations plan and track patient enrollment for clinical trials and TTC, a benchmarking solutions and analytics company that helps clients plan for and negotiate the costs of clinical trials. Also in 2012, the company purchased PharmaDeals Ltd., a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the pharmaceutical industry.
In 2013, acquired several companies to expand its portfolio of SaaS products: Incential Software, a provider of sales performance management technology services; 360 Vantage, which delivers multi-channel CRM software capabilities; Appature, which offers a relationship marketing platform; and Semantelli, a provider of social media analytics for the global healthcare industry.
In May 2015, IMS increased its software development capability by acquiring Dataline Software Ltd, a bespoke software development company and big data research specialist in the UK.
In April 2015, IMS Health completed the purchase of Cegedim's Customer Relationship Management (CRM) software and Strategic Data business for €396 million. Cegedim acquired the software and related business when it purchased Dendrite International in 2007.
In August 2015, IMS Health completed the purchase of Boston Biomedical Consultants, a provider of market data and market research covering the in vitro Diagnostics market
In May 2016, the company announced it would merge with Quintiles IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS.
On November 6, 2017, the company adopted the new name of IQVIA.
Quintiles
Quintiles was the world's largest provider of biopharmaceutical development and commercial outsourcing services. The company offered clinical data management, clinical trial execution services, pharmaceuticals, drug development, financial partnering, and commercialization expertise to companies in the biotechnology, pharmaceutical and healthcare sectors.
In 1982, Dennis Gillings founded and incorporated Quintiles Transnational in North Carolina. Quintiles Transnational established Quintiles Pacific Inc. and Quintiles Ireland Ltd. in 1990. In 1991 Quintiles GmbH was established in Germany and Quintiles Laboratories Ltd. was established in Atlanta, Georgia. In September 1996, Quintiles purchased Innovex Ltd. of Britain for $747.5 million in stock. Quintiles went public in 1997 and completed a successful secondary stock offering.
In 1974, Dennis Gillings signs the first contract to provide statistical and data management consulting for pharmaceutical clients.
In 1982, Quintiles, Inc., is incorporated in North Carolina.
In 1990, Quintiles Pacific Inc. and Quintiles Ireland Ltd. are established.
In 1991, Quintiles GmbH is established in Germany; Quintiles Laboratories Ltd. is established in Atlanta, Georgia.
In 1996, Quintiles buys Innovex Ltd. and BRI International Inc., becoming the world's largest CRO.
In 1997, Quintiles goes public, completing a successful secondary stock offering.
In 1998, Quintiles becomes the first company in the industry to break the $1 billion mark, when it reports net revenues of $1.19 billion.
In 1999, the company joins the S&P 500 Index.
In 2003, the Board of Directors agrees to merge with Pharma Services Holdings Inc; Quintiles becomes a private company.
In 2009, Quintiles opens new corporate headquarters in Durham, North Carolina.
In 2010, Quintiles opens new European headquarters in the UK and establishes operations in East Africa.
In 2011, Quintiles buys Advion Biosciences, a bioanalytical lab based out of Ithaca, New York.
In 2013, Quintiles filed for an IPO on 15 February in order to go public again; Quintiles begins trading on the New York Stock Exchange (NYSE) under ticker symbol Q."
Merger of IMS Health and Quintiles
In October 2016, Quintiles merged with IMS Health to form QuintilesIMS. In November 2017, the company adopted the new name of IQVIA.
The company is ranked 282nd on the Fortune 500 and 680th on the Forbes Global 2000.
Controversies
IMS Health's business of collecting and selling pharmaceutical sales data, even though they say it is anonymized, was under scrutiny from both the media and the legal system.
IMS Health v. Ayotte was a free speech case involving IMS Health.
Sorrell v. IMS Health Inc. was a case about physician-data privacy, which went to the U.S. Supreme Court. The court ruled in favor of the company.
IQVIA was contracted by the UK government's Office of National Statistics to provide data on the prevalence of COVID-19 infection in the population. Some users of the survey reported problems contacting IQVIA and arranging for testing. The problems with how the survey results were collected were criticised for potentially leading to biased data by New Scientist.
On July 17, 2023, the Federal Trade Commission sued to block IQVIA’s acquisition of Propel Media alleging in an administrative complaint that the acquisition would give IQVIA a market-leading position in health care programmatic advertising and would raise health-care prices for consumers. In December 2023, U.S. District Court Judge Edgardo Ramos issued an order granting the FTC’s motion for preliminary injunction to block the merger. Speaking in favor of the FTC, Ramos said, "The FTC has shown that there is a reasonable probability that the proposed acquisition will substantially impair competition in the relevant market and that the equities weigh in favor of injunctive relief." An administrative trial was scheduled to start on January 18, 2024. However, on January 5, 2024, IQVIA and Propel Media announced that they had mutually agreed to abandon the proposed merger.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
IQV Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
IQV Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
IQV Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
- Mocne kupno 8 28,6%
- Kup 14 50,0%
- Trzymaj 6 21,4%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
18 analityków · 2026-08-17Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $3.15 | $3.06 | 0.09% |
| 31 marca 2026 | $2.90 | $2.85 | 0.05% |
| 31 grudnia 2025 | $3.42 | $3.43 | -0.01% |
| 30 września 2025 | $3.00 | $3.00 | -0.00% |
| 30 czerwca 2025 | $2.81 | $2.80 | 0.01% |
| 31 marca 2025 | $2.70 | $2.66 | 0.04% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | — |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
| DHR | $161.82B | 45.3 | 2.9% | 14.7% | 7.1% | 59.1% |
| A | $41.43B | 32.0 | 6.7% | 18.8% | 20.6% | — |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B | $11.09B | $10.41B | $9.70B | $6.82B | $5.74B | $5.46B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $4.62B | $3.24B | $2.71B | $2.66B | |
| R&D Expense | · | · | · | · | · | · | · | · | · | · | $3M | $6M | |
| SG&A Expense | $2.00B | $1.99B | $2.05B | $2.07B | $1.96B | $1.79B | $1.73B | $1.72B | $1.62B | $1.02B | $815M | $781M | |
| Operating Income | $2.18B | $2.20B | $1.98B | $1.80B | $1.39B | $731M | $777M | $741M | $665M | $576M | $646M | $590M | |
| Interest Expense | $729M | $670M | $672M | $416M | $375M | $416M | $447M | $414M | $346M | $144M | $101M | $101M | |
| Interest Income | $45M | $47M | $36M | $13M | $6M | $6M | $9M | $8M | $7M | $4M | $4M | $4M | |
| Other Non-op | $99M | $90M | $124M | $-33M | $130M | $65M | $37M | $-5M | $-13M | $11M | $-2M | $8M | |
| Pretax Income | $1.59B | $1.67B | $1.46B | $1.36B | $1.13B | $373M | $352M | $328M | $294M | $416M | $539M | $501M | |
| Income Tax | $252M | $301M | $101M | $260M | $163M | $72M | $116M | $59M | $-992M | $325M | $159M | $149M | |
| Net Income | $1.36B | $1.37B | $1.36B | $1.09B | $966M | $279M | $191M | $259M | $1.28B | $72M | $387M | $357M | |
| EPS (Basic) | $7.91 | $7.57 | $7.39 | $5.82 | $5.05 | $1.46 | $0.98 | $1.27 | $5.86 | $0.48 | $3.15 | $2.78 | |
| EPS (Diluted) | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 | $1.43 | $0.96 | $1.24 | $5.74 | $0.47 | $3.08 | $2.72 | |
| Shares (Basic) | 171,900,000 | 181,300,000 | 183,800,000 | 187,600,000 | 191,400,000 | 191,300,000 | 195,100,000 | 203,700,000 | 217,800,000 | 149,100,000 | 123,000,000 | 128,000,000 | |
| Shares (Diluted) | 173,500,000 | 183,400,000 | 186,300,000 | 190,600,000 | 195,000,000 | 195,000,000 | 199,600,000 | 208,200,000 | 222,600,000 | 152,000,000 | 125,600,000 | 131,100,000 | |
| EBITDA | $3.33B | $3.32B | $3.10B | $2.93B | $2.66B | $2.02B | $1.98B | $1.88B | $1.73B | $931M | $774M | $711M |
Bilans 28
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.98B | $1.70B | $1.38B | $1.22B | $1.37B | $1.81B | $837M | $891M | $959M | $1.20B | $977M | $867M | |
| Short-term Investments | $161M | $141M | $120M | $93M | $111M | $88M | $62M | $47M | $46M | $40M | · | · | |
| Receivables | $3.40B | $3.20B | $3.38B | $2.92B | $2.55B | $2.41B | $2.58B | $2.39B | $2.10B | $1.71B | $1.17B | $975M | |
| Prepaid Expense | $162M | $154M | $141M | $151M | $156M | $159M | $138M | $151M | $146M | $123M | $51M | $45M | |
| Other Current Assets | · | · | · | · | · | · | · | $322M | $259M | $235M | $83M | $92M | |
| Current Assets | $6.25B | $5.83B | $5.60B | $4.98B | $4.76B | $5.09B | $4.13B | $3.87B | $3.55B | $3.34B | $2.41B | $2.15B | |
| PP&E (Net) | $533M | $535M | $523M | $532M | $497M | $482M | $458M | $434M | $440M | $406M | $188M | $190M | |
| PP&E (Gross) | $1.44B | $1.35B | $1.33B | $1.37B | $1.26B | $1.16B | $1.05B | $1.00B | $923M | $769M | $510M | $496M | |
| Accum. Depreciation | $905M | $819M | $803M | $840M | $765M | $673M | $597M | $567M | $483M | $363M | $322M | $306M | |
| Goodwill | $16.62B | $14.71B | $14.57B | $13.92B | $13.30B | $12.65B | $12.16B | $11.80B | $11.85B | $10.73B | $720M | $464M | |
| Intangibles | $4.96B | $4.50B | $4.84B | $4.82B | $4.94B | $5.21B | $5.51B | $5.95B | $6.59B | $6.39B | $368M | $280M | |
| Total Assets | $29.94B | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B | $23.25B | $22.55B | $22.86B | $21.21B | $3.93B | $3.30B | |
| Accounts Payable | · | · | · | · | · | · | · | $437M | $322M | $250M | $145M | $109M | |
| Accrued Liabilities | $2.97B | $2.95B | $2.85B | $2.67B | $2.36B | $2.23B | $1.94B | $1.86B | $1.66B | $1.49B | $761M | $734M | |
| Current Liabilities | $8.34B | $6.96B | $6.49B | $5.58B | $5.24B | $4.56B | $3.94B | $3.53B | $3.16B | $2.71B | $1.59B | $1.47B | |
| Capital Leases | $225M | $173M | $223M | $264M | $313M | $371M | $396M | · | · | · | $18.0K | $14.0K | |
| Deferred Tax | $179M | $196M | $202M | $464M | $410M | $338M | $646M | $627M | $786M | $2.04B | · | $62M | |
| Other Non-current Liabilities | $688M | $668M | $698M | $671M | $649M | $633M | $456M | $418M | $440M | $402M | $183M | $184M | |
| Total Liabilities | $23.31B | $20.83B | $20.57B | $19.57B | $18.65B | $18.28B | $16.99B | $15.60B | $14.61B | $12.35B | $4.26B | $4.00B | |
| Long-term Debt | $15.72B | $13.98B | $13.67B | $12.75B | $12.12B | $12.53B | $11.64B | $11.01B | $10.27B | $7.22B | $2.50B | $2.31B | |
| Total Debt | $15.72B | $13.98B | $13.67B | $12.75B | $12.12B | $12.53B | $11.64B | $11.01B | $10.22B | $7.20B | $2.47B | $2.29B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | $144M | |
| Retained Earnings | $7.42B | $6.07B | $4.69B | $3.33B | $2.24B | $1.28B | $998M | $807M | $538M | $-399M | $-462M | $-789M | |
| Treasury Stock | $11.36B | $10.10B | $8.74B | $7.74B | $6.57B | $6.17B | $5.73B | $4.77B | $3.37B | $1.00B | · | · | |
| AOCI | $-943M | $-1.04B | $-867M | $-727M | $-406M | $-205M | $-311M | $-224M | $49M | $-570M | $-111M | $-59M | |
| Stockholders' Equity | $6.50B | $6.07B | $6.11B | $5.76B | $6.04B | $6.28B | $6.26B | $6.71B | $8.00B | $8.63B | $-564M | $-704M | |
| Liabilities + Equity | $29.94B | $26.90B | $26.68B | $25.34B | $24.69B | $24.56B | $23.25B | $22.55B | $22.86B | $21.21B | $3.93B | $3.30B | |
| Shares Outstanding | 169,600,000 | 258,200,000 | 257,200,000 | 256,400,000 | 255,800,000 | 254,700,000 | 253,000,000 | 251,500,000 | 249,500,000 | 248,300,000 | 119,400,000 | 124,100,000 |
Przepływy pieniężne 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.14B | $1.11B | $1.12B | $1.13B | $1.26B | $1.29B | $1.20B | $1.14B | $1.01B | $289M | $128M | $121M | |
| Stock-based Comp | $247M | $206M | $217M | $194M | $170M | $95M | $146M | $113M | $106M | $106M | $38M | $30M | |
| Deferred Tax | $-180M | $-129M | $-269M | $-115M | $-138M | $-176M | $-157M | $-177M | $-1.22B | $115M | $18M | $-6M | |
| Amort. of Intangibles | $984M | $965M | $974M | $970M | $1.12B | $1.15B | $1.07B | $1.02B | $886M | $210M | $67M | $58M | |
| Restructuring | $105M | $67M | $84M | $28M | $20M | $52M | $75M | $68M | $63M | $71M | $30M | $9M | |
| Other Non-cash | $83M | $152M | $-282M | $-40M | $680M | $474M | $35M | $-82M | $-240M | $241M | $-95M | $-69M | |
| Operating Cash Flow | $2.65B | $2.72B | $2.15B | $2.26B | $2.94B | $1.96B | $1.42B | $1.25B | $970M | $860M | $476M | $433M | |
| CapEx | $603M | $602M | $649M | $674M | $640M | $616M | $582M | $459M | $369M | $164M | $78M | $83M | |
| Investing Cash Flow | $-2.31B | $-1.44B | $-1.60B | $-2.01B | $-2.10B | $-796M | $-1.19B | $-810M | $-1.19B | $1.73B | · | · | |
| Stock Repurchased | $1.24B | $1.35B | $992M | $1.17B | $406M | $447M | $949M | $1.41B | $2.62B | $1.10B | $515M | $415M | |
| Net Stock Activity | $-1.24B | $-1.35B | $-992M | $-1.17B | $-406M | $-447M | $-949M | $-1.41B | $-2.62B | $-1.10B | $-515M | $-415M | |
| Financing Cash Flow | $-150M | $-878M | $-382M | $-329M | $-1.24B | $-217M | $-276M | $-452M | $-72M | $-2.28B | · | · | |
| Net Change in Cash | $278M | $326M | $160M | $-150M | $-448M | $977M | $-54M | $-68M | $-239M | $221M | $110M | $90M | |
| Taxes Paid | · | $295M | $340M | $255M | $222M | $209M | $215M | $211M | $195M | $106M | $121M | $139M | |
| Free Cash Flow | $2.05B | $2.11B | $1.50B | $1.59B | $2.30B | $1.34B | $835M | $795M | $601M | $696M | $397M | $349M | |
| Levered FCF | $1.44B | $1.56B | $875M | $1.25B | $1.98B | $1.01B | $535M | $455M | $-777M | $656M | $326M | $420M |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% | 6.4% | 7.0% | 7.1% | 7.4% | 9.3% | 11.3% | 10.8% | |
| Net Margin | 8.3% | 8.9% | 9.1% | 7.6% | 7.0% | 2.5% | 1.7% | 2.5% | 13.4% | 1.7% | 6.8% | 6.5% | |
| Pretax Margin | 9.8% | 10.8% | 9.7% | 9.5% | 8.1% | 3.3% | 3.2% | 3.1% | 3.4% | 7.0% | 9.4% | 9.2% | |
| EBITDA Margin | 20.4% | 21.5% | 20.7% | 20.3% | 19.1% | 17.8% | 17.8% | 18.1% | 17.8% | 13.5% | 13.5% | 13.0% | |
| ROA | 4.8% | 5.1% | 5.2% | 4.4% | 3.9% | 1.2% | 0.83% | 1.1% | 6.0% | 0.92% | 10.7% | 11.2% | |
| ROE | 21.6% | 22.6% | 22.9% | 18.5% | 15.7% | 4.5% | 3.0% | 3.5% | 15.6% | 2.9% | -61.1% | -52.0% | |
| ROIC | 8.3% | 9.0% | 9.3% | 7.9% | 6.6% | 3.2% | 2.9% | 3.4% | 15.6% | 1.1% | 23.9% | 26.1% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 | 1.1 | 1.0 | 1.1 | 1.2 | 1.2 | 1.5 | 1.5 | |
| Quick Ratio | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 1.0 | 1.1 | 1.3 | 1.3 | |
| Debt / Equity | 2.4 | 2.3 | 2.2 | 2.2 | 2.0 | 2.1 | 1.9 | 1.6 | 1.3 | 0.8 | -4.4 | -3.3 | |
| LT Debt / Equity | 2.1 | 2.1 | 2.1 | 2.2 | 2.0 | 2.1 | 1.9 | 1.6 | 1.2 | 0.8 | -4.3 | -3.3 | |
| Interest Coverage | 3.0 | 3.3 | 2.9 | 4.3 | 3.7 | 1.8 | 1.7 | 1.8 | 2.1 | 4.5 | 6.4 | -5.9 |
Efektywność 2
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 1.6 | 1.7 | |
| Receivables Turnover | 4.9 | 4.7 | 4.8 | 5.3 | 5.6 | 4.6 | 4.5 | 4.6 | 5.3 | 4.8 | 5.4 | 5.7 |
Stopy Wzrostu 9
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 5.9% | 2.8% | 4.0% | 3.9% | 22.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 4.2% | 3.5% | 9.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 4.7% | 2.7% | 27.5% | 15.6% | 246.2% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 11.1% | 14.8% | 72.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 40.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -0.95% | 1.1% | 24.5% | 12.9% | 246.2% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 7.6% | 12.4% | 69.5% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 13
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B | $11.36B | $11.09B | $10.41B | $9.70B | $6.82B | $5.74B | $5.46B | |
| Net Income TTM | $1.36B | $1.37B | $1.36B | $1.09B | $966M | $279M | $191M | $259M | $1.28B | $72M | $387M | $357M | |
| Market Cap | $38.23B | $34.61B | $42.00B | $38.05B | $53.78B | $34.26B | $29.71B | $29.22B | $24.43B | $18.88B | $8.20B | $7.31B | |
| Enterprise Value | $51.81B | $46.75B | $54.17B | $49.49B | $64.42B | $44.89B | $40.46B | $39.29B | $33.65B | $24.85B | $9.69B | $8.73B | |
| P/E | 28.8 | 26.2 | 31.7 | 35.8 | 57.0 | 125.3 | 160.9 | 93.7 | 17.1 | 161.8 | 22.3 | 21.6 | |
| P/S | 2.3 | 2.2 | 2.8 | 2.6 | 3.9 | 3.0 | 2.7 | 2.8 | 2.5 | 2.8 | 1.4 | 1.3 | |
| P/B | 5.9 | 5.7 | 6.9 | 6.6 | 8.9 | 5.7 | 4.9 | 4.4 | 3.0 | 2.2 | -14.5 | -10.4 | |
| P / Cash Flow | 14.4 | 12.7 | 19.5 | 16.8 | 18.3 | 17.5 | 21.0 | 23.3 | 25.2 | 22.0 | 17.2 | 16.9 | |
| P / FCF | 18.6 | 16.4 | 28.0 | 24.0 | 23.4 | 25.5 | 35.6 | 36.8 | 40.6 | 27.1 | 20.6 | 20.9 | |
| EV / EBITDA | 15.6 | 14.1 | 17.5 | 16.9 | 24.2 | 22.2 | 20.4 | 20.9 | 19.4 | 26.7 | 12.5 | 12.3 | |
| EV / FCF | 25.3 | 22.1 | 36.1 | 31.2 | 28.0 | 33.4 | 48.5 | 49.4 | 56.0 | 35.7 | 24.4 | 25.0 | |
| EV / Revenue | 3.2 | 3.0 | 3.6 | 3.4 | 4.6 | 4.0 | 3.6 | 3.8 | 3.5 | 3.6 | 1.7 | 1.6 | |
| Earnings Yield | 3.5% | 3.8% | 3.1% | 2.8% | 1.8% | 0.80% | 0.62% | 1.1% | 5.9% | 0.62% | 4.5% | 4.6% |
Rachunek zysków i strat 15
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.37B | $4.15B | $4.36B | $4.10B | $4.02B | $3.83B | $3.96B | $3.90B | $3.81B | $3.74B | $3.87B | $3.74B | $3.73B | $3.65B | $3.74B | $3.56B | |
| Gross Profit | · | · | · | · | · | · | · | $915M | $863M | $827M | · | $862M | $850M | $802M | · | $812M | |
| SG&A Expense | $574M | $502M | $468M | $514M | $509M | $508M | $453M | $522M | $509M | $508M | $556M | $502M | $482M | $513M | $583M | $517M | |
| Operating Income | $506M | $514M | $627M | $553M | $506M | $496M | $626M | $550M | $520M | $506M | $501M | $481M | $524M | $471M | $379M | $472M | |
| Interest Expense | $197M | $192M | $193M | $189M | $182M | $165M | $171M | $170M | $163M | $166M | $181M | $181M | $169M | $141M | $128M | $108M | |
| Interest Income | $7M | $10M | $11M | $13M | $10M | $11M | $11M | $13M | $12M | $11M | $12M | $14M | $4M | $6M | $6M | $4M | |
| Other Non-op | $-12M | $-4M | $94M | $31M | $-11M | $-15M | $78M | $-44M | $67M | $-11M | $47M | $35M | $16M | $26M | $18M | $-8M | |
| Pretax Income | $301M | $328M | $537M | $408M | $323M | $323M | $544M | $349M | $436M | $340M | $373M | $349M | $375M | $362M | $275M | $360M | |
| Income Tax | $60M | $59M | $59M | $76M | $56M | $61M | $112M | $65M | $75M | $49M | $-102M | $51M | $81M | $71M | $48M | $70M | |
| Net Income | $256M | $274M | $514M | $331M | $266M | $249M | $437M | $285M | $363M | $288M | $469M | $303M | $297M | $289M | $227M | $283M | |
| EPS (Basic) | $1.54 | $1.63 | $3.00 | $1.94 | $1.55 | $1.42 | $2.43 | $1.57 | $1.99 | $1.58 | $2.56 | $1.66 | $1.61 | $1.56 | $1.23 | $1.52 | |
| EPS (Diluted) | $1.53 | $1.61 | $2.97 | $1.93 | $1.54 | $1.40 | $2.41 | $1.55 | $1.97 | $1.56 | $2.54 | $1.63 | $1.59 | $1.53 | $1.21 | $1.49 | |
| Shares (Basic) | 166,100,000 | 168,400,000 | -345,800,000 | 170,200,000 | 171,800,000 | 175,700,000 | -364,900,000 | 182,100,000 | 182,200,000 | 181,900,000 | -369,300,000 | 182,900,000 | 184,400,000 | 185,800,000 | -377,200,000 | 186,500,000 | |
| Shares (Diluted) | 167,300,000 | 169,800,000 | -348,800,000 | 171,700,000 | 173,200,000 | 177,400,000 | -369,400,000 | 184,200,000 | 184,300,000 | 184,300,000 | -374,500,000 | 185,500,000 | 186,700,000 | 188,600,000 | -383,300,000 | 189,400,000 | |
| EBITDA | $798M | $802M | · | $839M | $782M | $761M | · | $828M | $789M | $770M | · | $778M | $783M | $724M | · | $720M |
Bilans 25
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.91B | $1.95B | $1.98B | $1.81B | $2.04B | $1.74B | $1.70B | $1.57B | $1.54B | $1.44B | · | $1.22B | $1.38B | $1.49B | · | $1.27B | |
| Short-term Investments | $171M | $156M | $161M | $158M | $149M | $136M | $141M | $140M | $133M | $131M | · | $108M | $110M | $104M | · | $87M | |
| Receivables | $3.35B | $3.35B | $3.40B | $3.27B | $3.34B | $3.27B | $3.20B | $3.20B | $3.25B | $3.43B | · | $3.23B | $3.14B | $3.06B | · | $2.64B | |
| Prepaid Expense | $220M | $167M | $162M | $177M | $200M | $166M | $154M | $195M | $191M | $173M | · | $177M | $179M | $165M | · | $176M | |
| Current Assets | $6.23B | $6.22B | $6.25B | $5.98B | $6.34B | $5.91B | $5.83B | $5.63B | $5.62B | $5.65B | · | $5.21B | $5.33B | $5.33B | · | $4.75B | |
| PP&E (Net) | $547M | $516M | $533M | $525M | $536M | $533M | $535M | $513M | $503M | $513M | · | $498M | $510M | $520M | · | $507M | |
| PP&E (Gross) | · | · | $1.44B | · | · | · | $1.35B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $905M | · | · | · | $819M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $16.60B | $16.54B | $16.62B | $15.95B | $15.61B | $15.03B | $14.71B | $15.09B | $14.48B | $14.52B | $14.57B | $14.29B | $14.18B | $14.02B | $13.92B | $13.18B | |
| Intangibles | $4.75B | $4.80B | $4.96B | $4.71B | $4.60B | $4.50B | $4.50B | $4.73B | $4.61B | $4.72B | · | $4.91B | $4.94B | $4.76B | · | $4.72B | |
| Total Assets | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B | $27.18B | $26.40B | $26.57B | · | $25.98B | $26.04B | $25.74B | · | $24.22B | |
| Accrued Liabilities | · | · | $2.97B | · | · | · | $2.95B | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $8.81B | $8.33B | $8.34B | $8.51B | $7.57B | $7.18B | $6.96B | $6.99B | $6.62B | $6.45B | · | $6.59B | $6.54B | $6.66B | · | $5.25B | |
| Capital Leases | $242M | $232M | $225M | $233M | $210M | $177M | $173M | $188M | $192M | $204M | · | $217M | $242M | $255M | · | $259M | |
| Deferred Tax | $173M | $159M | $179M | $207M | $216M | $197M | $196M | $128M | $149M | $164M | · | $365M | $367M | $421M | · | $560M | |
| Other Non-current Liabilities | $645M | $617M | $688M | $698M | $671M | $676M | $668M | $612M | $632M | $595M | · | $679M | $703M | $641M | · | $561M | |
| Total Liabilities | $23.58B | $23.33B | $23.31B | $22.44B | $22.85B | $21.34B | $20.83B | $20.21B | $19.68B | $20.23B | · | $20.17B | $20.29B | $19.81B | · | $18.88B | |
| Long-term Debt | $16.00B | $15.83B | $15.72B | $14.96B | $15.49B | $14.33B | $13.98B | $13.51B | $13.26B | $13.54B | · | $13.63B | $13.78B | $13.18B | · | $12.39B | |
| Total Debt | $16.00B | $15.83B | · | $14.96B | $15.49B | $14.33B | · | $13.51B | $13.26B | $13.54B | · | $13.63B | $13.78B | $13.18B | · | $12.39B | |
| Retained Earnings | $7.96B | $7.70B | $7.42B | $6.91B | $6.58B | $6.31B | $6.07B | $5.63B | $5.34B | $4.98B | · | $4.22B | $3.92B | $3.62B | · | $3.11B | |
| Treasury Stock | $12.32B | $11.91B | $11.36B | $11.14B | $11.14B | $10.53B | $10.10B | $8.94B | $8.74B | $8.74B | · | $8.51B | $8.36B | $7.87B | · | $7.71B | |
| AOCI | $-964M | $-968M | $-943M | $-928M | $-882M | $-978M | $-1.04B | $-826M | $-949M | $-911M | · | $-903M | $-760M | $-731M | · | $-898M | |
| Stockholders' Equity | $6.17B | $6.22B | $6.50B | $6.16B | $5.78B | $5.98B | $6.07B | $6.97B | $6.71B | $6.34B | · | $5.80B | $5.75B | $5.93B | $5.76B | $5.35B | |
| Liabilities + Equity | $29.88B | $29.68B | $29.94B | $28.73B | $28.63B | $27.32B | $26.90B | $27.18B | $26.40B | $26.57B | · | $25.98B | $26.04B | $25.74B | · | $24.22B | |
| Shares Outstanding | 164,600,000 | 166,900,000 | 169,600,000 | 170,300,000 | 170,000,000 | 174,100,000 | 176,100,000 | 181,600,000 | 182,300,000 | 182,200,000 | 257,200,000 | 182,500,000 | 183,100,000 | 185,500,000 | 256,400,000 | 185,800,000 |
Przepływy pieniężne 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $292M | $288M | $317M | $286M | $276M | $265M | $303M | $278M | $269M | $264M | $316M | $297M | $259M | $253M | $357M | $248M | |
| Stock-based Comp | $95M | $65M | $60M | $55M | $60M | $72M | $48M | $54M | $48M | $56M | $45M | $47M | $50M | $75M | $58M | $61M | |
| Deferred Tax | $-36M | $-38M | $-48M | $-46M | $-45M | $-41M | $-15M | $-34M | $-14M | $-66M | $-152M | $-47M | $-43M | $-27M | $-63M | $-24M | |
| Restructuring | $63M | $51M | $24M | $20M | $32M | $29M | $-4M | $28M | $28M | $15M | $17M | $30M | $20M | $17M | $13M | $4M | |
| Other Non-cash | · | $29M | · | · | · | $23M | · | · | · | $-20M | · | · | · | $-173M | · | · | |
| Operating Cash Flow | $558M | $618M | $735M | $908M | $443M | $568M | $885M | $721M | $588M | $522M | $747M | $583M | $402M | $417M | $560M | $863M | |
| CapEx | $198M | $127M | $174M | $136M | $151M | $142M | $164M | $150M | $143M | $145M | $179M | $146M | $160M | $164M | $171M | $165M | |
| Investing Cash Flow | $-381M | $-196M | $-1.10B | $-550M | $-346M | $-305M | $-310M | $-599M | $-221M | $-314M | $-212M | $-573M | $-596M | $-222M | $-477M | $-717M | |
| Stock Repurchased | $398M | $552M | $212M | $0 | $657M | $375M | $1.15B | $200M | $0 | $0 | $229M | $144M | $490M | $129M | $65M | $210M | |
| Net Stock Activity | · | $-552M | · | · | · | $-375M | · | · | · | $0 | · | · | · | $-129M | · | · | |
| Financing Cash Flow | $-214M | $-433M | $535M | $-572M | $145M | $-258M | $-375M | $-137M | $-260M | $-106M | $-420M | $-144M | $95M | $87M | $-193M | $-251M | |
| Net Change in Cash | $-38M | $-33M | $166M | $-225M | $299M | $38M | $130M | $27M | $101M | $68M | $152M | $-158M | $-112M | $278M | $-58M | $-154M | |
| Free Cash Flow | · | $491M | · | · | · | $426M | · | · | · | $377M | · | · | · | $253M | · | · | |
| Levered FCF | · | $334M | · | · | · | $292M | · | · | · | $235M | · | · | · | $140M | · | · |
Rentowność 8
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | · | · | 23.5% | 22.6% | 22.1% | · | 23.1% | 22.8% | 22.0% | · | 22.8% | |
| Operating Margin | 11.6% | 12.4% | · | 13.5% | 12.6% | 13.0% | · | 14.1% | 13.6% | 13.5% | · | 12.9% | 14.1% | 12.9% | · | 13.2% | |
| Net Margin | 5.9% | 6.6% | · | 8.1% | 6.6% | 6.5% | · | 7.3% | 9.5% | 7.7% | · | 8.1% | 8.0% | 7.9% | · | 7.9% | |
| Pretax Margin | 6.9% | 7.9% | · | 10.0% | 8.0% | 8.4% | · | 9.0% | 11.4% | 9.1% | · | 9.3% | 10.1% | 9.9% | · | 10.1% | |
| EBITDA Margin | 18.3% | 19.3% | · | 20.5% | 19.5% | 19.9% | · | 21.2% | 20.7% | 20.6% | · | 20.8% | 21.0% | 19.8% | · | 20.2% | |
| ROA | 0.88% | 0.96% | · | 1.2% | 0.97% | 0.92% | · | 1.1% | 1.4% | 1.1% | · | 1.2% | 1.2% | 1.1% | · | 1.2% | |
| ROE | 4.3% | 4.5% | · | 5.0% | 4.3% | 4.0% | · | 4.5% | 5.8% | 4.7% | · | 5.4% | 5.3% | 4.9% | · | 5.1% | |
| ROIC | 1.8% | 1.9% | · | 2.1% | 2.0% | 2.0% | · | 2.2% | 2.2% | 2.2% | · | 2.1% | 2.1% | 2.0% | · | 2.1% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.8 | · | 0.9 | |
| Quick Ratio | 0.6 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 0.7 | 0.7 | 0.8 | · | 0.7 | 0.7 | 0.7 | · | 0.8 | |
| Debt / Equity | 2.6 | 2.5 | · | 2.4 | 2.7 | 2.4 | · | 1.9 | 2.0 | 2.1 | · | 2.3 | 2.4 | 2.2 | · | 2.3 | |
| LT Debt / Equity | 2.2 | 2.2 | · | 2.1 | 2.5 | 2.2 | · | 1.8 | 1.8 | 2.0 | · | 2.1 | 2.2 | 2.0 | · | 2.3 | |
| Interest Coverage | 2.6 | 2.7 | · | 2.9 | 2.8 | 3.0 | · | 3.2 | 3.2 | 3.0 | · | 2.7 | 3.1 | 3.3 | · | 4.4 |
Efektywność 2
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.2 | 1.1 | · | 1.2 | 1.2 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 1.4 |
Wycena (TTM) 13
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $16.64B | $16.10B | · | $15.84B | $15.56B | $15.28B | · | $15.18B | $15.02B | $14.85B | · | $14.68B | $14.48B | $14.32B | · | $14.06B | |
| Net Income TTM | $1.13B | $1.12B | · | $1.13B | $1.16B | $1.19B | · | $1.24B | $1.25B | $1.18B | · | $1.17B | $1.12B | $1.15B | · | $1.12B | |
| Market Cap | $31.80B | $28.46B | · | $32.35B | $26.79B | $30.69B | · | $43.03B | $38.55B | $46.08B | · | $35.91B | $41.16B | $36.89B | · | $33.66B | |
| Enterprise Value | $45.72B | $42.19B | · | $45.33B | $40.09B | $43.15B | · | $54.83B | $50.13B | $58.04B | · | $48.21B | $53.44B | $48.47B | · | $44.69B | |
| P/E | 29.2 | 26.3 | · | 29.6 | 24.4 | 27.2 | · | 35.3 | 31.3 | 40.1 | · | 31.5 | 37.8 | 32.9 | · | 31.0 | |
| P/S | 1.9 | 1.8 | · | 2.0 | 1.7 | 2.0 | · | 2.8 | 2.6 | 3.1 | · | 2.4 | 2.8 | 2.6 | · | 2.4 | |
| P/B | 5.2 | 4.6 | · | 5.3 | 4.6 | 5.1 | · | 6.2 | 5.7 | 7.3 | · | 6.2 | 7.2 | 6.2 | · | 6.3 | |
| P / Cash Flow | · | 46.1 | · | · | · | 54.0 | · | · | · | 88.3 | · | · | · | 88.5 | · | · | |
| P / FCF | · | 58.0 | · | · | · | 72.1 | · | · | · | 122.2 | · | · | · | 145.8 | · | · | |
| EV / EBITDA | 57.3 | 52.6 | · | 54.0 | 51.3 | 56.7 | · | 66.2 | 63.5 | 75.4 | · | 62.0 | 68.3 | 67.0 | · | 62.1 | |
| EV / FCF | · | 85.9 | · | · | · | 101.3 | · | · | · | 153.9 | · | · | · | 191.6 | · | · | |
| EV / Revenue | 2.7 | 2.6 | · | 2.9 | 2.6 | 2.8 | · | 3.6 | 3.3 | 3.9 | · | 3.3 | 3.7 | 3.4 | · | 3.2 | |
| Earnings Yield | 3.4% | 3.8% | · | 3.4% | 4.1% | 3.7% | · | 2.8% | 3.2% | 2.5% | · | 3.2% | 2.6% | 3.0% | · | 3.2% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $16.31B | $15.40B | $14.98B | $14.41B | $13.87B |
| Marża Operacyjna % | 13.4% | 14.3% | 13.2% | 12.5% | 10.0% |
| Zysk netto | $1.36B | $1.37B | $1.36B | $1.09B | $966M |
| Rozwodniony EPS | $7.84 | $7.49 | $7.29 | $5.72 | $4.95 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 2.4 | 2.3 | 2.2 | 2.2 | 2.0 |
| Wskaźnik bieżący | 0.7 | 0.8 | 0.9 | 0.9 | 0.9 |
| Wskaźnik Szybkości | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $2.05B | $2.11B | $1.50B | $1.59B | $2.30B |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 1 176 emitentów · $16.9B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 132 (-13 vs poprzedni kw.) | 103 (-63 vs poprzedni kw.) | 389 (-15 vs poprzedni kw.) | 420 (+23 vs poprzedni kw.) | -3.2M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2 107 074 341 | 10 905 053 | 12,50% | Akcje |
| STATE STREET CORP | $1 450 742 906 | 7 508 244 | 8,61% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 449 535 087 | 7 501 993 | 8,60% | Akcje |
| Artisan Partners Limited Partnership | $916 526 317 | 4 743 434 | 5,44% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $751 515 288 | 3 907 352 | 4,46% | Akcje |
| NORGES BANK | $437 632 480 | 2 264 944 | 2,60% | Akcje |
| Longview Partners (Guernsey) LTD | $289 976 847 | 1 500 760 | 1,72% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $282 111 725 | 1 460 055 | 1,67% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $280 214 615 | 1 643 102 | 1,66% | Akcje |
| LYRICAL ASSET MANAGEMENT LP | $243 436 719 | 1 259 894 | 1,44% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $241 535 241 | 1 250 053 | 1,43% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $240 910 560 | 1 246 820 | 1,43% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $204 721 978 | 1 059 526 | 1,21% | Akcje |
| LAZARD ASSET MANAGEMENT LLC | $188 339 728 | 974 742 | 1,12% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $181 113 608 | 937 344 | 1,07% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $160 725 420 | 831 826 | 0,95% | Akcje |
| CADIAN CAPITAL MANAGEMENT, LP | $157 619 601 | 815 752 | 0,94% | Akcje |
| FIL Ltd | $153 554 253 | 794 712 | 0,91% | Akcje |
| JARISLOWSKY, FRASER Ltd | $149 227 880 | 785 658 | 0,89% | Akcje |
| GREENHAVEN ASSOCIATES INC | $148 401 655 | 768 045 | 0,88% | Akcje |
| 1832 Asset Management L.P. | $143 802 826 | 744 244 | 0,85% | Akcje |
| AMERIPRISE FINANCIAL INC | $142 211 800 | 735 972 | 0,84% | Akcje |
| FMR LLC | $135 375 060 | 700 627 | 0,80% | Akcje |
| Balyasny Asset Management L.P. | $135 333 607 | 700 412 | 0,80% | Akcje |
| Boston Partners | $133 444 690 | 690 636 | 0,79% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $121 523 014 | 628 936 | 0,72% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $113 104 610 | 585 374 | 0,67% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $106 359 117 | 550 456 | 0,63% | Akcje |
| EARNEST PARTNERS LLC | $105 901 563 | 548 088 | 0,63% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $99 841 411 | 516 724 | 0,59% | Akcje |
| Swiss National Bank | $92 490 550 | 478 680 | 0,55% | Akcje |
| BlackRock, Inc. | $91 938 713 | 475 824 | 0,55% | Akcje |
| CIBC Bancorp USA Inc. | $91 205 076 | 471 352 | 0,54% | Akcje |
| D. E. Shaw & Co., Inc. | $90 085 733 | 466 234 | 0,53% | Akcje |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $79 369 559 | 410 773 | 0,47% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $78 508 764 | 406 318 | 0,47% | Akcje |
| National Pension Service | $72 645 503 | 375 973 | 0,43% | Akcje |
| Ilex Capital Partners (UK) LLP | $71 680 176 | 370 977 | 0,43% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $70 949 418 | 367 195 | 0,42% | Akcje |
| California Public Employees Retirement System | $70 656 690 | 365 680 | 0,42% | Akcje |
| Vanguard Global Advisers, LLC | $69 529 444 | 359 846 | 0,41% | Akcje |
| Quantinno Capital Management LP | $69 138 831 | 357 824 | 0,41% | Akcje |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $68 883 914 | 356 505 | 0,41% | Akcje |
| Legal & General Group Plc | $67 679 555 | 350 272 | 0,40% | Akcje |
| Assenagon Asset Management S.A. | $65 786 773 | 340 476 | 0,39% | Akcje |
| CI INVESTMENTS INC. | $65 379 079 | 338 366 | 0,39% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $64 474 036 | 333 682 | 0,38% | Akcje |
| RHUMBLINE ADVISERS | $64 175 589 | 332 138 | 0,38% | Akcje |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $61 424 638 | 317 900 | 0,36% | Akcje |
| Capital World Investors | $61 228 906 | 316 887 | 0,36% | Akcje |
| FIRST MANHATTAN CO. LLC. | $60 389 365 | 312 542 | 0,36% | Akcje |
| Man Group plc | $57 113 707 | 295 589 | 0,34% | Akcje |
| Cornerstone Investment Partners, LLC | $56 162 291 | 290 665 | 0,33% | Akcje |
| Point72 Asset Management, L.P. | $53 998 807 | 279 468 | 0,32% | Akcje |
| Qube Research & Technologies Ltd | $53 924 997 | 279 086 | 0,32% | Akcje |
| Vulcan Value Partners, LLC | $50 209 376 | 259 856 | 0,30% | Akcje |
| GOLDMAN SACHS GROUP INC | $47 369 345 | 245 158 | 0,28% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $44 584 443 | 261 431 | 0,26% | Akcje |
| Danica Pension, Livsforsikringsaktieselskab | $43 968 177 | 227 555 | 0,26% | Akcje |
| SEB Asset Management AB | $41 578 752 | 215 189 | 0,25% | Akcje |
| COUNTRY TRUST BANK | $41 040 701 | 212 404 | 0,24% | Akcje |
| BANK OF AMERICA CORP /DE/ | $40 135 272 | 207 718 | 0,24% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $39 462 000 | 204 232 | 0,23% | Akcje |
| Associated Banc-Corp | $38 755 873 | 200 579 | 0,23% | Akcje |
| Freestone Grove Partners LP | $38 705 830 | 200 320 | 0,23% | Akcje |
| ASSETMARK, INC | $38 066 693 | 197 012 | 0,23% | Akcje |
| Trajan Wealth LLC | $35 265 548 | 182 515 | 0,21% | Akcje |
| Robeco Institutional Asset Management B.V. | $33 903 348 | 175 465 | 0,20% | Akcje |
| HARRIS ASSOCIATES L P | $33 507 826 | 173 418 | 0,20% | Akcje |
| UBS Group AG | $32 389 275 | 167 629 | 0,19% | Akcje |
| Dana Investment Advisors, Inc. | $32 065 825 | 165 955 | 0,19% | Akcje |
| Woodline Partners LP | $31 980 808 | 165 515 | 0,19% | Akcje |
| KENSICO CAPITAL MANAGEMENT CORP | $31 881 300 | 165 000 | 0,19% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $30 940 319 | 160 130 | 0,18% | Akcje |
| BARCLAYS PLC | $30 871 145 | 159 772 | 0,18% | Akcje |
| Act Two Investors LLC | $30 672 902 | 158 746 | 0,18% | Akcje |
| AVIVA PLC | $29 357 847 | 151 940 | 0,17% | Akcje |
| MML INVESTORS SERVICES, LLC | $28 789 342 | 148 998 | 0,17% | Akcje |
| Meridiem Capital Partners LP | $27 945 409 | 144 630 | 0,17% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $27 653 453 | 143 119 | 0,16% | Akcje |
| Gotham Asset Management, LLC | $27 184 508 | 140 692 | 0,16% | Akcje |
| LPL Financial LLC | $26 931 587 | 139 383 | 0,16% | Akcje |
| Candriam S.C.A. | $26 917 640 | 139 445 | 0,16% | Akcje |
| CIBC Asset Management Inc | $26 395 011 | 136 606 | 0,16% | Akcje |
| Howard Capital Management Group, LLC | $26 033 014 | 134 733 | 0,15% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $25 336 358 | 131 127 | 0,15% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24 914 763 | 128 620 | 0,15% | Akcje |
| Banco Santander, S.A. | $23 956 575 | 123 986 | 0,14% | Akcje |
| MORGAN STANLEY | $23 730 050 | 122 813 | 0,14% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 514 874 | 121 700 | 0,14% | Opcja sprzedaży |
| TUDOR INVESTMENT CORP ET AL | $23 098 292 | 119 544 | 0,14% | Akcje |
| Compagnie Lombard Odier SCmA | $22 951 639 | 118 785 | 0,14% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $22 870 437 | 134 106 | 0,14% | Akcje |
| Cetera Investment Advisers | $22 677 210 | 117 365 | 0,13% | Akcje |
| Artemis Investment Management LLP | $22 412 167 | 115 993 | 0,13% | Akcje |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $22 184 748 | 114 816 | 0,13% | Akcje |
| VAN ECK ASSOCIATES CORP | $21 593 301 | 111 755 | 0,13% | Akcje |
| Andra AP-fonden | $20 704 409 | 121 405 | 0,12% | Akcje |
| GDS Wealth Management | $20 556 096 | 106 387 | 0,12% | Akcje |
| Parkman Healthcare Partners LLC | $20 444 801 | 105 811 | 0,12% | Akcje |
Insiderzy spółki 31 insiderów · 14 dyrektorzy generalni · 16 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Ari Bousbib | Chairman, Chief Executive Officer & President Power of Attorney | 29 lipca 2026 M | 835 941 | 0 | 10 | $-38 553 192 |
| Michael R. Mcdonnell | EVP and CFO | 3 października 2016 A | 44 106 | 0 | 0 | $0 |
| Richard W Staub | President, Research & Development Solutions Power of Attorney | 3 sierpnia 2026 S | 13 312 | 0 | 1 | $-1 279 740 |
| Bhavik Patel | President, MedTech and Consumer Health Power of Attorney | 31 lipca 2026 S | 1 348 | 0 | 1 | $-436 426 |
| John D Ratliff | President and COO | 18 listopada 2013 X | 0 | 0 | 0 | $0 |
| Kevin K Gordon | EVP and COO | 9 czerwca 2016 X | 17 899 | 0 | 0 | $0 |
| Keriann Cherofsky | SVP, Corporate Controller Power of Attorney | 29 lipca 2026 S | 2 989 | 0 | 1 | $-136 827 |
| Eric Sherbet | Executive Vice President, General Counsel Power of Attorney | 29 lipca 2026 S | 20 999 | 0 | 1 | $-1 245 800 |
| Iii James H Erlinger | Exec VP and GC | 3 października 2016 A | 18 024 | 0 | 0 | $0 |
| Thomas Pike | Vice Chair, Pres R&D Solutions | 3 października 2016 A | 185 460 | 0 | 0 | $0 |
| Kevin C Knightly | Pres Info & Tech Solutions | 3 października 2016 A | 26 826 | 0 | 0 | $0 |
| Charles Edward Williams | Sr VP and Controller | 3 marca 2016 A | 3 911 | 0 | 0 | $0 |
| Derek M. Winstanly | Exec VP & Chief Cust & Gov Ofc | 13 lutego 2014 X | 229 500 | 0 | 0 | $0 |
| Michael I. Mortimer | Exec VP & Chief Admin Officer | 18 listopada 2013 S | 25 000 | 0 | 0 | $0 |
| Morris Leslie Wims | Dyrektor | 14 lipca 2026 A | — | 0 | 0 | $0 |
| Jim Fasano | Dyrektor | 14 lipca 2026 A | — | 0 | 0 | $0 |
| Colleen A Goggins | Dyrektor | 14 lipca 2026 A | — | 0 | 0 | $0 |
| John G Danhakl | Dyrektor | 14 lipca 2026 A | 0 | 0 | 0 | $0 |
| John Connaughton | Dyrektor | 2 grudnia 2021 G | 0 | 0 | 0 | $0 |
| Dennis B Ph D Gillings | Dyrektor | 28 sierpnia 2017 S | 84 067 | 0 | 0 | $0 |
| Ronald A Rittenmeyer | Dyrektor | 3 października 2016 A | 54 849 | 0 | 0 | $0 |
| Annie H. Lo | Dyrektor | 12 maja 2016 P | 2 062 | 0 | 0 | $0 |
| John M. Leonard | Dyrektor | 5 maja 2016 A | 2 316 | 0 | 0 | $0 |
| Michael J Evanisko | Dyrektor | 5 maja 2016 A | 5 346 | 0 | 0 | $0 |
| Jack M Greenberg | Dyrektor | 5 maja 2016 A | 2 930 | 0 | 0 | $0 |
| Leonard D Schaeffer | Dyrektor | 5 maja 2016 A | 65 896 | 0 | 0 | $0 |
| Christopher R Gordon | Dyrektor | 5 sierpnia 2015 S | 9 944 017 | 0 | 0 | $0 |
| Mireille Gillings | Dyrektor | 19 maja 2015 X | 11 663 929 | 0 | 0 | $0 |
| Canada Pension Plan Investment Board | Posiadacz 10% | 18 września 2018 J | 1 569 600 | 0 | 0 | $0 |
| DENNIS & MIREILLE GILLINGS FOUNDATION | Posiadacz 10% | 19 maja 2015 S | 103 556 | 0 | 0 | $0 |
| Gillings Limited Partnership | Posiadacz 10% | 10 listopada 2014 S | 0 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Canada Pension Plan Investment Board, CPP Investment Board Private Holdings Inc. ×8 zgłoszenia | 13 sierpnia 2019 | — | Pierwotne zgłoszenie | — | SEC |
| TPG Group Holdings (SBS) Advisors, Inc., TPG Advisors VI, Inc., TPG Advisors V, Inc., TPG Biotech Advisors, Inc., David Bonderman, James G. Coulter ×9 zgłoszenia | 12 marca 2019 | — | Pierwotne zgłoszenie | Struktura kapitałowa | SEC |
| Quintiles Transnational Holdings Inc. | 13 maja 2016 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| OR | 13 maja 2016 | — | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 177 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| EKG · First Trust Exchange-Traded Fund II | 8,26% | 1 204 NS | 30 czerwca 2026 | N-PORT |
| HEAL · Global X Funds | 4,72% | 6 483 NS | 31 maja 2026 | N-PORT |
| BSJQ · Invesco Exchange-Traded Self-Indexe… | 3,06% | 24 615 000 | 21 sierpnia 2026 | Dziennie |
| RSPH · Invesco Exchange-Traded Fund Trust | 2,04% | 65 208 SH | 21 sierpnia 2026 | Dziennie |
| FLV · AMERICAN CENTURY ETF TRUST | 1,91% | 37 019 NS | 31 maja 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,89% | 13 621 SH | 21 sierpnia 2026 | Dziennie |
| RUNN · Strategic Trust | 1,75% | 33 257 NS | 31 maja 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,73% | 5 832 NS | 30 kwietnia 2026 | N-PORT |
| EPMB · Harbor ETF Trust | 1,57% | 447 NS | 30 kwietnia 2026 | N-PORT |
| EPMV · Harbor ETF Trust | 1,36% | 380 NS | 30 kwietnia 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,03% | 726 NS | 30 kwietnia 2026 | N-PORT |
| LRGC · AB Active ETFs, Inc. | 0,89% | 60 947 NS | 31 maja 2026 | N-PORT |
| NUMV · Nushares ETF Trust | 0,83% | 22 672 NS | 30 kwietnia 2026 | N-PORT |
| THMZ · Lazard Active ETF Trust | 0,82% | 2 293 NS | 30 czerwca 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,80% | 44 382 NS | 30 kwietnia 2026 | N-PORT |
| RFFC · ALPS ETF Trust | 0,75% | 1 218 NS | 31 maja 2026 | N-PORT |
| IYH · iShares Trust | 0,66% | 99 195 SH | 21 sierpnia 2026 | Dziennie |
| COWZ · Pacer Funds Trust | 0,62% | 709 284 NS | 30 kwietnia 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,62% | 1 821 NS | 30 kwietnia 2026 | N-PORT |
| IMCV · iShares Trust | 0,58% | 26 899 SH | 21 sierpnia 2026 | Dziennie |
| VOE · VANGUARD INDEX FUNDS | 0,56% | 1 072 113 SH | 19 sierpnia 2026 | Dziennie |
| ITAN · EA Series Trust | 0,55% | 2 710 NS | 29 maja 2026 | N-PORT |
| IXJ · iShares Trust | 0,52% | 87 943 SH | 21 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,48% | 510 171 SH | 19 sierpnia 2026 | Dziennie |
| RXL · ProShares Trust | 0,45% | 1 768 NS | 31 maja 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,44% | 78 509 NS | 30 kwietnia 2026 | N-PORT |
| IWS · iShares Trust | 0,41% | 250 393 SH | 21 sierpnia 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,40% | 7 214 NS | 30 kwietnia 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,39% | 3 383 NS | 30 kwietnia 2026 | N-PORT |
| EVUS · iShares Trust | 0,36% | 5 323 SH | 21 sierpnia 2026 | Dziennie |
| SUSA · iShares Trust | 0,32% | 50 767 SH | 21 sierpnia 2026 | Dziennie |
| CVMC · Morgan Stanley ETF Trust | 0,31% | 1 653 NS | 30 czerwca 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,31% | 3 616 975 SH | 19 sierpnia 2026 | Dziennie |
| IWR · iShares Trust | 0,30% | 677 410 SH | 21 sierpnia 2026 | Dziennie |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,30% | 8 582 000 | 21 sierpnia 2026 | Dziennie |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,29% | 6 499 NS | 31 maja 2026 | N-PORT |
| IMCB · iShares Trust | 0,29% | 19 156 SH | 21 sierpnia 2026 | Dziennie |
| SIZE · iShares Trust | 0,27% | 4 598 SH | 21 sierpnia 2026 | Dziennie |
| RSP · Invesco Exchange-Traded Fund Trust | 0,26% | 1 025 042 SH | 21 sierpnia 2026 | Dziennie |
| EUSA · iShares, Inc. | 0,26% | 19 768 SH | 21 sierpnia 2026 | Dziennie |
| DFVE · DoubleLine ETF Trust | 0,25% | 411 NS | 30 czerwca 2026 | N-PORT |
| XOEF · iShares Trust | 0,23% | 209 SH | 21 sierpnia 2026 | Dziennie |
| PY · Principal Exchange-Traded Funds | 0,23% | 2 572 NS | 30 czerwca 2026 | N-PORT |
| SPXD · DBX ETF Trust | 0,22% | 81 NS | 31 maja 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,21% | 79 706 NS | 30 kwietnia 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,21% | 72 385 NS | 30 kwietnia 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0,20% | 19 216 NS | 31 maja 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,18% | 4 875 NS | 30 kwietnia 2026 | N-PORT |
| USXF · iShares Trust | 0,17% | 9 914 SH | 21 sierpnia 2026 | Dziennie |
| OALC · Unified Series Trust | 0,16% | 2 166 NS | 31 maja 2026 | N-PORT |